Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review-Reference-Cited by-同舟云学术

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review

Published:2021-12-06 Issue: Volume: Page:
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Meijboom Rosanne W.,Gardarsdottir Helga,Egberts Toine C. G.,Giezen Thijs J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-021-00508-4.pdf

Reference82 articles.

1. Harbord M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn’s Colitis. 2017;11(7):769–84. https://doi.org/10.1093/ecco-jcc/jjx009.

2. Gomollón F, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis. 2017;11(1):3–25. https://doi.org/10.1093/ecco-jcc/jjw168.

3. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77. https://doi.org/10.1136/annrheumdis-2016-210715.

4. European Medicines Agency. Guideline on similar biological medicinal products. 2014.

5. Crosby M, Tadrous M, Gomes T. Potential cost implications of mandatory non-medical switching policies for biologics for rheumatic conditions and inflammatory bowel disease in Canada. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.2042.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Title and abstract screening for literature reviews using large language models: an exploratory study in the biomedical domain;Systematic Reviews;2024-06-15

2. Recommendations on TNFα inhibitor biosimilar use in clinical practice: a comparison of European gastroenterology IBD guidance;Expert Opinion on Biological Therapy;2023-03-23

3. Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar;Therapeutic Advances in Gastroenterology;2023-01

4. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System;Scientific Reports;2022-11-15